摘要
目的 评价新一代氟喹诺酮类药物司帕沙星对耐多药肺结核病 (MDR- TB)的治疗作用。方法 将 6 0例 MDR- TB患者随机平分为两组 :治疗组用司帕沙星 0 .3qd,对照组用左氧氟沙星 0 .2 tid,疗程 12月 ,同时辅以其他抗痨药物治疗。结果 有效率治疗组 86 .7% ,优于对照组 80 % ,痰菌阴转率 73.3% ,优于对照组 70 % ,两组相比无显著差异性 (p>0 .0 5 )。
Objective To study the therapeutic efficacy of new generation fluoroquinolones drugSparfloxacin in treating MDR TB.Methods Sixty cases with MDR TB were randomly divided into two groups One group(n=30)was treated with Sparfloxacin 0.3qd,the other group (n=30) was treated with Levofloxacin 0.2g tid,the course of treatment of each group lasted 12 months,and also with the other anti tuberculsis drugs in the Same time.Results The effective rates were 86.5% in Sparfloxacin group and 80% in Levofloxacin group the suptum M.tuberculosis clearance rates were 73.3% in sparflxacin in group and 70% in levefloxacin group.There was no significant difference in the two group(p>0.05).Conclusion Sparfoxacin is an effective drug for MDR TB among other quinolones.
出处
《临床肺科杂志》
2003年第2期127-128,共2页
Journal of Clinical Pulmonary Medicine
关键词
司帕沙星
左氧氨沙星
耐多药肺结核
临床疗效
治疗
Sqarfloxacin Levofloxacin multiple drug resistant pulmonary tuberculosis(MDR TB) clincal efficacy
